CAMPATH-1H (C-1H) is widely used in vivo and/or in vitro for T cell depletion in hematopoietic SCT. This humanised monoclonal antibody is specific for CD52, a marker coexpressed on the majority of human lymphocytes with CD48 and other glycosylphosphatidyl-inositol (GPI) anchored proteins. We detected CD52/CD48 dual expression on 499% of CD3 þ lymphocytes from normal individuals and all 15 post-SCT patients whose transplants did not utilise C-1H. By contrast, 23/26 patients with transplants involving C-1H (in vivo, in vitro or both) exhibited populations lacking CD52 expression that accounted for 49.7% (4.2-86.2%) of the CD3 þ lymphocytes (median and range) in samples evaluated at a median of 2 months post-SCT. Most CD52 À cells also lacked CD48 expression. These GPI À T cells were of either donor or mixed donor/recipient origin. They were predominant in the early months after SCT at times of profound lymphopenia and inversely correlated with the recovery of the absolute lymphocyte count (r ¼ À0.663, Po0.0001). The presence of CD52 À cells has been correlated previously with clinical outcome after CAMPATH therapy for both malignant and nonmalignant diseases. Bone Marrow Transplantation (2005) 36, 237-244.
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CAMPATH-1H (C-1H) is a humanised IgG1 antibody, which has lower immunogenicity and prolonged half-life after infusion compared to the rat antibody (CAMPATH-1G) from which it is derived. [1] [2] [3] [4] Its target antigen is CD52, which is expressed on virtually all lymphocytes but not stem cells; a distribution pattern that allows the application of this antibody to T cell depletion (TCD) in the SCT setting. [5] [6] [7] The CD52-protein lacks a transmembrane region and is tethered to cell membranes via a glycosylphosphatidyl-inositol (GPI) anchor. 8 GPI-anchored proteins are present on many blood cell types, including CD55 and CD59 on erythrocytes, CD16 on neutrophils, and CD48, CD55 and CD59 on lymphocytes. 9 Several studies of patients in nontransplant settings (rheumatoid arthritis (RA), B cell CLL and B cell nonHodgkin's lymphoma (NHL)) have shown that C-1H treatment can result in the emergence of T cells lacking expression of CD52 and that of other GPI-anchored proteins. [10] [11] [12] [13] These cells resemble those found in paroxysmal nocturnal haemoglobinuria (PNH), an acquired clonal stem cell disorder characterised by chronic intravascular haemolysis and bone marrow failure. 14 In PNH there is a total or partial deficiency of GPI-anchored membrane proteins, with blood cell subsets affected to varying extents. 9, 15 The involvement of lymphoid cells is less well recognised than that of myeloid lineages, but GPI-deficient T cells have been shown to comprise 0.2-30% of the T-cell compartment in a high proportion of PNH patients (84%). Similar proportions of GPI-deficient NK and B cells were also observed. [16] [17] [18] Little is known about the role of GPI-anchored proteins on lymphocytes, despite CD52 being present at a level of approximately 500 000 molecules per cell, 5, 19 although defects in their expression do not appear to affect activation or proliferation in vitro. 10, 17 However, CD52 À cell emergence after C-1H therapy may have clinical relevance: in patients treated for RA, the presence of CD52 À T cells was correlated with prolonged remission while in CLL a role has been postulated for CD8
þ CD52 þ cells in controlling relapse. 10, 13 We therefore decided to monitor the presence of these cells following SCT where C-1H was used for prophylaxis of GVHD and graft rejection, in comparison to a control population who did not receive C-1H. Serial sampling allowed us to examine the persistence and, in some cases, the donor/recipient haemopoietic origin of these cells. þ cells exceeded 10% of the lymphocyte population and (3) greater than 1000 gated lymphocytes on flow cytometry. The stem cell source was BM in 21 cases and PBSC in 20. Donors and patients were matched for 10 antigens (HLA-A, B, C, DR and DQ) by PCR with sequence-specific primers to the allelic level. Donors were matched siblings (21 cases) or unrelated donors (13 matched and seven mismatched). In 26 cases the patients or their stem cell donations were treated with C-1H (Schering AG, Berlin, Germany). For in vivo conditioning, this included a range of daily dosing schedules within the range 0.2-0.3 mg/kg or 10-30 mg over 2-5 days, resulting in an overall median total dose of 48.9 mg (range 11.4-102.0 mg overall, 9.9-54.9 mg for children and 42.0-90.0 mg for adults). TCD of the donor material involved addition of C-1H in vitro ('in the bag', five cases) or CD34 selection of stem cells prior to infusion in seven cases (by CliniMACS selection, Miltenyi Biotech). TCD by C-1H in vitro consisted of addition of 20 mg to the final product followed by incubation at 221C for 30 min. The product was then infused within 30 min following premedication with methylprednisolone, paracetamol and chlorpheniramine. Where CD34 selection was performed, T cell addbacks of 5 Â 10 4 -10 6 /kg were infused along with the TCD donor material. The policies of our unit for prophylaxis against GVHD and cytomegalovirus infection have been detailed previously. [20] [21] [22] Patients were serially monitored for immune reconstitution parameters and compared to a panel of normal blood donors.
Materials and methods

Patient cohort and sample collection
Flow cytometry
Staining of whole blood was performed using CD3-RPE Cy5, CD48-FITC and CD52-PE (all from Serotec, Oxford, UK) or isotype controls obtained from Serotec (RPE Cy5 and FITC) or Immunotech (PE) (Luton, UK). Antibody incubation was performed for 25 min. Lysis solution (BD Biosciences, Oxford, UK) was then added and the samples vortexed and incubated for 10 min. All incubations were performed in the dark and at room temperature. Samples were then pelleted and washed once with wash buffer, consisting of cold calcium/magnesium-free PBS (Gibco, Life Technologies, Paisley, Scotland, UK) supplemented with 0.1% sodium azide (BDH, Poole, UK). Cells were fixed using wash buffer supplemented with 1% paraformaldehyde (BDH). Samples were stored at 41C and flow cytometric analysis performed within 24 h using a FACS Calibur Flow Cytometer and Cell Quest Software (BD Biosciences). A population of gated lymphocytes, as determined by forward vs side scatter properties, were analysed for cell surface expression of CD3, CD48 and CD52. However, many patients were lymphopenic in the early post transplant period, so these results were restricted to those patients from whom at least one sample was available within 4 months of transplantation in which the CD3 þ population accounted for 410% of the lymphocytes. This minimised the risk of misleading percentages derived from low cell numbers. Absolute lymphocyte counts (ALC) were obtained from the Haematology Laboratory of the United Bristol Healthcare Trust and absolute numbers of CD3 þ subsets derived by multiplying the ALC by the percentage expression of CD3 on gated lymphocytes.
Immunomagnetic sorting of cells
Some patient samples were subjected to immunomagnetic cell sorting in order to separate CD3 þ CD52 À and CD3 þ CD52 þ cells. This was performed using anti-human CD3 Dynal bead selection followed by a two-step selection for CD52 using CAMPATH (unconjugated rat anti human CD52, Serotec) and sheep anti-rat immunoglobulin Dynal beads (Dynal, Oslo, Norway), according to the manufacturer's instructions. The fractions were analysed by flow cytometry to confirm the purity of each subset, using antibodies to CD4 (FITC, Beckman Coulter, High Wycombe, UK), CD8 (RPE-Cy5, Serotec) and CD52.
Chimeric analysis
Chimeric analysis was performed as described previously. 23, 24 Briefly, DNA was extracted using the Qiamp DNA mini kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions and DNA quantification performed by spectrophotometry. Donor and recipient DNA were amplified in a multiplex reaction containing primer pairs for 16 polymorphic STR markers (Powerplex 16 system, Promega, Madison, WI, USA). The allelic lengths and relative positions of donor and recipient alleles determined the suitability of each marker for chimerism evaluation. Post transplant chimerism was determined using the beaded samples in single locus reactions using primers for a minimum of two selected informative markers (Sigma, Poole, UK). Fluorescent data were collected on the ABI Prism 3100 Genetic analyser using the collection software and analysed with Genescan Software (Applied Biosystems, Warrington, UK). The relative percentages of donor and recipient DNA present in sorted cell populations were determined. 24 This analysis was applied to sorted cell
Statistical analysis
The lymphocyte subset constitution between treatment groups and normal individuals were compared using the Kruskal-Wallis test. Where differences were identified, these were further examined using one-way analysis of variance with post hoc test. When only two groups were compared, the Mann-Whitney test was used. In order to assess whether the proportion of GPI-deficient T cells correlated with the ALC or CD3 þ counts the bivariate Pearson coefficient was calculated (SPSS 12.0 for Windows, Apache software foundation).
Results
CD52 expression on T cells from normal individuals and SCT recipients
The proportion of CD3 þ T lymphocytes expressing CD52 was examined in a panel of 22 normal blood donors. Only 0.05% (0-1.0%) of CD3 þ cells failed to express CD52 ( Figure 1 ; Table 1 ). In total, 41 SCT recipients were then examined, 26 with and 15 without C-1H utilisation in the transplant regimen. Of the 26 patients with transplants involving C-1H, 23 showed greater percentages of CD3 þ lymphocytes lacking CD52 expression than controls (Figure 2a and b) . These cells were present at differing levels between patients: at the time of the first evaluable sample (0.6-3.9 months post-SCT), CD52
À cells accounted for 47.8% (0.9-86.2%) of the CD3 þ lymphocytes. Three of the 26 patients receiving SCT involving C-1H and all 15 patients with transplants not involving C-1H showed a pattern of CD52 expression on CD3 þ lymphocytes, which was indistinguishable from that observed in normal individuals. Based on C-1H treatment and whether CD52 À T cells were detected, patients were assigned to one of three groups designated Table 1 ). The SCT characteristics of these groups of patients are displayed in Table 2 . Where possible, 10 000 gated lymphocytes were acquired. This was dictated by patients' ALC and fell in the range 1000-10 000 (median 7000), while for normals the range of values was the same, with a median of 10 000.
Expression of CD48 and CD52 on T cells
CD52 is normally expressed on lymphocytes with other GPI-anchored proteins such as CD48. In order to be confident that any differences in CD52 expression were due to a true global defect in GPI-anchored proteins (rather than the tail of a normal distribution curve for CD52 expression), three colour staining was performed to monitor the expression of CD3, CD48 and CD52. 9 In the panel of normal individuals, 99.9% (99.3-100%) of CD3 þ cells were positive for both CD48 and CD52 ( Figure 3 ; Table 1 ). The patient group with SCTs not involving C-1H (C-1H untreated GPI þ ) also exhibited this pattern (99.7% of CD3 þ cells were positive for both CD52 and CD48). In contrast, CD48 staining of CD3 þ T cells in the C-1H treated GPI Table 1 ). The SCT characteristics of the C-1H treated GPI À patients are displayed in Table 3 . This group of 23 patients exhibiting PNH-like T cells included 18 treated with C-1H in vivo only (two of whom received CD34 selected grafts), two treated with C-1H ex vivo alone (UPN 14 and 15) and a further three who received C-1H treated donations in addition to in vivo C-1H (UPN 5, 6 and 11). This group consisted of 11 children (o18 years) and 12 adults, and 12 BM and 11 PBSC transplants and included five matched sibling and 18 unrelated donor transplants (six of which were mismatched).
Persistence of CD52
À T cells in C-1H treated patients
Of the 23 patients demonstrating GPI-deficient T cells (UPNs 1-7, 11-12 and 14-15), 11 had more than five blood samples taken (median 8, range 5-15) over a period of 9.5 (3.5-19.3) months post-SCT, which allowed monitoring of the persistence of these cells. Of these patients, six were in vivo C-1H treated alone (UPN 1-4, 7 and 12), three received both in vivo and ex vivo C-1H (UPN 5, 6 and 11) and two received ex vivo but not in vivo C-1H (UPN 14 and 15). Figure 5 shows the persistence pattern of GPI-deficient CD3 þ CD52 À cells as a percentage of the CD3 þ cell subset for these 11 patients. The majority of patients treated with C-1H in vivo possessed CD52 À populations (expressed as a proportion of the CD3 þ population), which declined over time. The rate of decline varied between patients, ranging from those in whom CD52 À T cells were only observed in the first sample to others with levels of 410% at 410 months post-SCT (UPN 4, 5 and 14). The proportion of CD3 þ CD52 À cells after in vivo C-1H treatment was inversely correlated with ALC (r ¼ À0.663, n ¼ 56,
Po0.0001) or CD3
þ counts (r ¼ À0.518, n ¼ 61, Po0.0001). Only one patient showed stable absolute counts of CD3
À cells (UPN 4, data not shown).
Origin of CD3
þ CD52 À cells T cell chimerism was assessed as part of the clinical management of a subset of the patients on one or two occasions. The results are shown in Table 4 . On occasions, patients 12, 14 and 15 showed majority donor CD3 chimerism (86-100%) at times when CD52 À cells constituted 61.8-84.6% of their CD3 population, implying that CD52 À cells were largely or completely of donor origin. UPN 12 had in vivo C-1H depletion and UPN 14 and 15 had ex vivo depletion.
In several patients, at times of substantial mixed chimerism, CD52
À and CD52 þ fractions of peripheral blood CD3 cells were isolated by magnetic cell sorting and subjected to chimeric analysis. Sorted populations of UPN 12 were both 50% donor in origin. In UPN 4 CD3 þ CD52 À cells were 71% donor and CD3 þ CD52 þ T cells were 44% donor. Thus, both donor and recipient haemopoiesis were contributing to the development of CD52 À T cells in these patients.
CD52 expression on cells other than T cells
Expression of CD52 on B cells and NK cells was analysed in a pooled fashion by investigating CD3 À lymphocytes. CD52
À lymphocytes comprised 12.8% (1.9-51.5%) of CD3 À lymphocytes in normals but only 6% (0.5-44.2%) in C-1H treated GPI À patients. Unlike CD3 þ lymphocytes, it was not possible to distinguish any effect of C-1H in the generation of GPI-deficient CD3 À lymphocytes. Furthermore, staining of GPI-anchored proteins on red cells (CD55 and CD59), monocytes (CD14) and neutrophils (CD16) did not show any GPI À cell populations (data not shown).
Discussion
CD52 is expressed at high density (approximately 5 Â 10 5 antibody binding sites per cell) on over 95% of peripheral blood lymphocytes, 5,19 the density being higher on T cells than B or NK cells. 7 In PNH the presence of GPI-deficient clones is well documented within erythroid and myeloid cells. 9, 16 T cells are, however, also affected: GPI-deficient cells (negative for CD48 and CD59) comprised 0.2-30% of the T-cell compartment in 84 and 100% of two series of patients with PNH. 16, 18 These abnormal T cells have been shown to persist in two patients with PNH (for more than 10 and 25 years, respectively). 25 GPI-deficient T cells appear to be rare in normal individuals. They were not observed by conventional flow cytometry in two studies, 16, 25 but have been reported in another study where a selection step (use of aerolysin which The presence of high proportions of CD52 À T cells has, however, been reported following treatment for RA, 10 CLL/NHL 13 and CLL. 11 We now report the finding of GPI-deficient cells (accounting for 0.4-82.6% (median of 50%) of the T cells) in 85% of patients receiving C-1H either as part of conditioning therapy and/or as in vitro TCD, but not in other SCT patients tested. The proportion of these cells declined over time in inverse proportion to the absolute lymphocyte and CD3 counts, but CD52
À cells were present in some patients to beyond 10 months post-SCT. This skewing towards CD52 negativity in comparison to normals was not observed in CD3
À lymphocytes and we could not find GPI À erythroid or myeloid cells. Just one patient showed a significant rise in the proportion of CD52 À cells following first detection: from 16.6% of CD3 þ cells at 1.4 months to 65.7% at 3.5 months. Relapse of T-ALL occurred 6 weeks after the last observation and it is entirely possible that a CD52 À clone(s) was responsible although this could not be tested. This would have been in keeping with other case reports where four patients relapsed with CD52
À leukaemia having presented with CD52 þ T-cell prolymphocytic leukaemia (n ¼ 3) and B cell ALL (n ¼ 1), respectively. [27] [28] [29] The high proportion of C-1H-treated patients exhibiting CD52
À cells agrees well with findings after therapy for CLL (10/15 patients had CD52
À cells) but stands in contrast to the findings of Brett et al in RA patients. This latter group documented the emergence of CD52 À T cells in 3/25 patients being treated for RA despite generally higher dosing (range 60-400 mg). 10 In these patients, CD52 À cells were present at peak levels in the range 80-100% of CD4 þ T cells and 30-90% of CD8 þ T cells at 1 month into treatment and persisted throughout the 20 months of study.
The mechanism underlying development of CD52 À T cells after C-1H treatment is not known. The only patient studied in detail, from those with CD52 À T cells in the CLL series mentioned above, was shown to have a mutation of the PIG-A gene. 11 Highly sensitive PCR demonstrated the presence of cells bearing PIG-A mutation at very low frequency and thought to have predated C-1H therapy. By contrast, in patients treated for RA using C-1H, PIG-A mutations were excluded in clones derived from those who developed CD52 À T cells. 30 We have not tested whether the CD52 À cells arising post-C-1H therapy in SCT harbour mutations of the PIG-A gene, but consider this to be one important avenue of future investigation.
The potential clinical relevance of CD52 À cells is suggested by previous papers from different clinical scenarios. 13 In C-1H-treated RA patients continued disease remission was not correlated with CD4 depletion, as many patients relapsed despite persisting CD4 lymphopenia. 10, 31 However, the three patients (from 25) who had CD52
À T cells showed the longest disease remission in the series. Osterborg et al also noted that two CLL patients who demonstrated clonal expansion within the CD8 þ CD52 À population had sustained remission and hypothesised a regulatory role in controlling B cell tumour growth.
It could also be argued that CD52 À host T cells could drive rejection processes by evading C-1H therapy. For example, one previous case report (after use of CAM-PATH-1G during conditioning therapy) found an expansion of recipient CD3 þ CD8 þ CD52 À T cells at the time of graft rejection. 32 These cells were thought to be 'ADCCresistant' due to their lack of CD52 expression. This was not the mechanism by which CD52 À T cells arose in the present study as no cases of rejection were observed, these cells generally declined over time and, where studied, they were of donor or mixed donor/recipient rather than recipient origin.
It seems likeliest that the presence of CD52 À T cells acts as an inverse surrogate for immune reconstitution. We hypothesised that those showing high percentages of these cells would have proliferation of the few T cell clones, which have survived the presence of C-1H. This would certainly be consistent with the inverse correlation observed between the proportion of CD52 À cells and ALC. If so, these patients might be expected to show high rates of infection. Our data did agree with recent observations of a high incidence of CMV reactivation following in vivo use of C-1H: 33 this occurred in four of six at risk patients (ie patient, donor or both CMV seropositive). However, no correlation was apparent between high proportions of CD52 À cells and risk of CMV reactivation or other infections in this study. The power of these observations is greatly limited by the size of the study and the small number of patients who lacked CD52
À cells in the C-1H-treated group.
In conclusion, this study showed that GPI À T cells appeared after in vitro or in vivo use of C-1H in SCT. These cells were predominant at times of profound lymphopenia, declining with post transplant follow-up as the normal GPI þ T cell population reasserted itself. While the functional significance of these cells is not known, they could have relevance for the incidence of infection, autoimmune phenomena or rates of relapse. We propose that larger studies are now required, looking also at correlations with serum C1-H levels and stratification according to absolute CD52 À T cell counts. 
